GlassScriptPhysician profile
John Latona
NPI 1497700983
$18,060.13
in general payments reported to CMS, 2019-2025
35 companies · $2,175 in 2025
The $2,175 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,928 · 2020: $935 · 2021: $1,768 · 2022: $2,142 · 2023: $2,021 · 2024: $7,091 · 2025: $2,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,575 · Debt Forgiveness: $4,612 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,575.21 |
| Debt Forgiveness | $4,612.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Digital Innovations LLC | $4,612.00 | 2024 | Veracity Surgical |
| Alcon Vision LLC | $4,073.87 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Mallinckrodt Hospital Products INC. | $1,185.34 | 2022-2025 | Acthar |
| Abbvie INC. | $1,151.54 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $969.90 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $908.19 | 2019-2021 | |
| Allergan, INC. | $784.79 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $705.51 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Oyster Point Pharma, INC. | $591.22 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $515.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $335.90 | 2019-2023 | |
| Sight Sciences, INC. | $275.87 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ani Pharmaceuticals, INC. | $256.22 | 2024-2025 | Purified Cortrophin Gel |
| Kala Pharmaceuticals, INC. | $227.93 | 2020-2022 | |
| Harrow Eye, LLC | $212.37 | 2025 | Vevye |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $167.40 | 2022-2023 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $158.75 | 2021-2023 | Forum |
| Dompe US, INC. | $124.55 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $109.57 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $107.55 | 2023-2025 | Tecnis Simplicity, Baerveldt Glaucoma Implant (250) |
| New World Medical,INC. | $100.78 | 2021-2024 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Eyevance Pharmaceuticals LLC | $99.24 | 2019-2021 | |
| Ocular Therapeutix, INC. | $81.69 | 2023-2024 | Dextenza |
| Ivantis, INC | $56.45 | 2020-2021 | |
| Astellas Pharma US INC | $46.18 | 2024 | Izervay |
| Thea Pharma INC. | $40.75 | 2023-2025 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $28.31 | 2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Glaukos Corporation | $24.79 | 2024 | Idose |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $17.74 | 2025 | Tepezza |
| Alimera Sciences, INC. | $17.59 | 2024 | Yutiq, Iluvien |
| Shire North American Group INC | $16.91 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.86 | 2019 | |
| Carl Zeiss Meditec, INC. | $13.57 | 2019 | |
| Rxsight INC | $5.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Latona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.